Literature DB >> 116384

Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS).

K A Schumacher, H G Classen, M Späth.   

Abstract

In serum incubated at 36 degrees C for 18-24 hours a factor (DAS) develops which on intravenous injection into cats evokes platelet aggregation followed by an increase in pulmonary vascular resistance (PVR). This change in PVR is mediated via the platelets since it significantly correlates with the preinjection platelet count. There is evidence that phosphatidic acids (PA) and lysophosphatidic acids (LPA) are the active components of DAS. Investigations performed on platelet-rich plasma from man, cat, pig, dog, rabbit, guinea pig, and rat demonstrate that only human and feline platelets exposed to PA or to LPA are aggregated. Feline platelets are more sensitive to either compound than are the platelets from men; however, human platelets exhibit two exceptional properties, a) the sensitivity rapidly declines with time, b) pretreatment with subthreshold concentrations of LPA or PA induces a specific tachyphylaxis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 116384

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  22 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 2.  Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling.

Authors:  Yutong Zhao; Viswanathan Natarajan
Journal:  Biochim Biophys Acta       Date:  2012-07-15

3.  LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.

Authors:  Péter Tibor Dancs; Éva Ruisanchez; Andrea Balogh; Cecília Rita Panta; Zsuzsanna Miklós; Rolf M Nüsing; Junken Aoki; Jerold Chun; Stefan Offermanns; Gábor Tigyi; Zoltán Benyó
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

4.  Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.

Authors:  Akira Tokumura; Junya Sinomiya; Seishi Kishimoto; Tamotsu Tanaka; Kentaro Kogure; Takayuki Sugiura; Kiyoshi Satouchi; Keizo Waku; Kenji Fukuzawa
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

5.  Platelet phospholipase D is activated by protein kinase C via an integrin alpha IIb beta 3-independent mechanism.

Authors:  E A Martinson; S Scheible; A Greinacher; P Presek
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

6.  The bioactive phospholipid lysophosphatidic acid is released from activated platelets.

Authors:  T Eichholtz; K Jalink; I Fahrenfort; W H Moolenaar
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

Review 7.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

8.  Acetal phosphatidic acids: novel platelet aggregating agents.

Authors:  J P Brammer; M H Maguire; E J Walaszek; R A Wiley
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

Review 9.  Roles of lysophosphatidic acid in cardiovascular physiology and disease.

Authors:  Susan S Smyth; Hsin-Yuan Cheng; Sumitra Miriyala; Manikandan Panchatcharam; Andrew J Morris
Journal:  Biochim Biophys Acta       Date:  2008-06-10

10.  Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma.

Authors:  A Tokumura; M Miyake; O Yoshimoto; M Shimizu; K Fukuzawa
Journal:  Lipids       Date:  1998-10       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.